AACR20: ctDNA shows promise for early detection and prevention of cancer

Written by Rachel Jenkins, Future Science Group

Two studies, due to be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I (27–28 April 2020), have suggested promising conclusions relating to the use of circulating tumor DNA (ctDNA) for early detection and prevention of cancer. Read the full summaries below. Want regular AACR updates straight to your inbox? Become a member of Oncology Central.   Is it possible to predict cancer and tissue of origin (TOO) using circulating free DNA (cfDNA)? Researchers from a multi-institute team, led by the Mayo Clinic Florida (FL, USA), have investigated a cfDNA test that has demonstrated the potential...

To view this content, please register now for access

It's completely free